Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KNSA
stocks logo

KNSA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
196.64M
+60.47%
0.495
-512.51%
203.79M
+47.91%
0.350
+218.18%
214.62M
+36.88%
0.480
+108.7%
Estimates Revision
The market is revising Upward the revenue expectations for Kiniksa Pharmaceuticals International, plc (KNSA) for FY2025, with the revenue forecasts being adjusted by 5.08% over the past three months. During the same period, the stock price has changed by 14.79%.
Revenue Estimates for FY2025
Revise Upward
up Image
+5.08%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.34%
In Past 3 Month
Stock Price
Go Up
up Image
+14.79%
In Past 3 Month
Wall Street analysts forecast KNSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KNSA is 52.00 USD with a low forecast of 44.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast KNSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KNSA is 52.00 USD with a low forecast of 44.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 40.990
sliders
Low
44.00
Averages
52.00
High
60.00
Current: 40.990
sliders
Low
44.00
Averages
52.00
High
60.00
Goldman Sachs
Buy
upgrade
$45 -> $55
2025-10-29
Reason
Goldman Sachs
Price Target
$45 -> $55
2025-10-29
upgrade
Buy
Reason
Goldman Sachs raised the firm's price target on Kiniksa to $55 from $45 and keeps a Buy rating on the shares.
Citi
Geoff Meacham
Buy
maintain
$45 -> $50
2025-10-17
Reason
Citi
Geoff Meacham
Price Target
$45 -> $50
2025-10-17
maintain
Buy
Reason
Citi analyst Geoff Meacham raised the firm's price target on Kiniksa to $50 from $45 and keeps a Buy rating on the shares as part of a Q3 preview for the biotechnology group. The firm believes investor interest in the smaller cap biotech names is building, which could set the group up well for 2026.
TD Cowen
Buy
initiated
$60
2025-09-29
Reason
TD Cowen
Price Target
$60
2025-09-29
initiated
Buy
Reason
TD Cowen initiated coverage of Kiniksa with a Buy rating and $60 price target. The firm says Kiniksa is at a "pivotal stage" as Arcalyst's launch continues to ramp while KPL-387 could offer more favorable dosing. This could extend the franchise and significantly improve the company's earnings, the analyst tells investors in a research note.
Jefferies
Buy
maintain
$45 -> $54
2025-07-29
Reason
Jefferies
Price Target
$45 -> $54
2025-07-29
maintain
Buy
Reason
Jefferies raised the firm's price target on Kiniksa to $54 from $45 and keeps a Buy rating on the shares after what the firm points out was "another 'beat & raise'" report following a "greatly positive" Q1. The firm sees strong commercial execution, continued growth on all launch metrics, and meaningful upside from further deepening the penetration into the target population as well as potential expansion into a larger population of patients, the analyst tells investors.
Wells Fargo
NULL -> Overweight
upgrade
$30 -> $42
2025-07-09
Reason
Wells Fargo
Price Target
$30 -> $42
2025-07-09
upgrade
NULL -> Overweight
Reason
Wells Fargo raised the firm's price target on Kiniksa to $42 from $30 and keeps an Overweight rating on the shares. The firm's Q2 Arcalyst estimates of $146M are in line with the Street, and it forecasts continued growth through 2025. As KPL-387's trial initiates in mid-25, all eyes are on Arcalyst this year and its market share in early lines, adds Wells.
Wedbush
David Nierengarten
Buy
Reiterates
$34
2025-04-16
Reason
Wedbush
David Nierengarten
Price Target
$34
2025-04-16
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Kiniksa Pharmaceuticals International PLC (KNSA.O) is 21.86, compared to its 5-year average forward P/E of -289.71. For a more detailed relative valuation and DCF analysis to assess Kiniksa Pharmaceuticals International PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-289.71
Current PE
21.86
Overvalued PE
977.41
Undervalued PE
-1556.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-26.79
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
123.21
Undervalued EV/EBITDA
-176.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
11.40
Current PS
0.00
Overvalued PS
46.20
Undervalued PS
-23.41
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

KNSA News & Events

Events Timeline

(ET)
2025-10-28
07:35:40
Kiniksa anticipates that its ongoing operating strategy will continue to generate positive cash flow.
select
2025-10-28
07:35:06
Kiniksa Adjusts FY25 ARCALYST Net Product Revenue Forecast to $670M-$675M
select
2025-10-28
07:34:06
Kiniksa announces Q3 earnings per share of 23 cents, below consensus estimate of 37 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-19NASDAQ.COM
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?

  • Biotech Sector Performance: The biotech sector is experiencing significant stock surges and advancements in trials and regulatory filings, highlighting the importance of distinguishing between short-term price fluctuations and long-term value for investors.

  • Notable Stock Highlights: Several biotech companies, including Olema Pharmaceuticals, Owlet Inc., and Rigel Pharmaceuticals, have reached new 52-week highs, driven by positive trial results and strategic offerings.

  • Upcoming Developments: Companies like Jazz Pharmaceuticals and Tarsus Pharmaceuticals are preparing for important regulatory submissions and clinical trials, indicating ongoing innovation and potential market impact.

  • Financial Outlooks: Firms such as Natera and Kiniksa Pharmaceuticals have provided updated revenue guidance for 2025, reflecting growth expectations and strategic advancements in their respective fields.

[object Object]
Preview
5.0
10-23Yahoo Finance
Kiniksa Pharmaceuticals Executive Offloads Shares Valued at $1,962,781, Recent SEC Filing Reveals

  • Sale of Shares: Michael R Megna, the Chief Accounting Officer, sold 50,490 shares of Kiniksa Pharma on October 20, 2025.

  • Date of Transaction: The transaction took place on October 20, 2025.

[object Object]
Preview
3.0
10-22NASDAQ.COM
Analysis Indicates VBK Could Reach $342

  • Vanguard Small-Cap Growth ETF Analysis: The Vanguard Small-Cap Growth ETF (VBK) has an implied analyst target price of $341.80, indicating a potential upside of 12.07% from its current trading price of $304.99.

  • Notable Holdings with Upside Potential: Key underlying holdings of VBK, such as Kiniksa Pharmaceuticals (KNSA), NET Power Inc (NPWR), and Kymera Therapeutics (KYMR), show significant upside potential based on analyst target prices, with KNSA having a target 24.84% higher than its current price.

  • Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to future downgrades if they do not align with market realities.

  • Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analyst targets in light of recent developments in the companies and their respective industries.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Kiniksa Pharmaceuticals International PLC (KNSA) stock price today?

The current price of KNSA is 40.99 USD — it has increased 0.99 % in the last trading day.

arrow icon

What is Kiniksa Pharmaceuticals International PLC (KNSA)'s business?

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.

arrow icon

What is the price predicton of KNSA Stock?

Wall Street analysts forecast KNSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KNSA is 52.00 USD with a low forecast of 44.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Kiniksa Pharmaceuticals International PLC (KNSA)'s revenue for the last quarter?

Kiniksa Pharmaceuticals International PLC revenue for the last quarter amounts to 180.86M USD, increased 61.17 % YoY.

arrow icon

What is Kiniksa Pharmaceuticals International PLC (KNSA)'s earnings per share (EPS) for the last quarter?

Kiniksa Pharmaceuticals International PLC. EPS for the last quarter amounts to 0.23 USD, decreased -227.78 % YoY.

arrow icon

What changes have occurred in the market's expectations for Kiniksa Pharmaceuticals International PLC (KNSA)'s fundamentals?

The market is revising Upward the revenue expectations for Kiniksa Pharmaceuticals International, plc (KNSA) for FY2025, with the revenue forecasts being adjusted by 5.08% over the past three months. During the same period, the stock price has changed by 14.79%.
arrow icon

How many employees does Kiniksa Pharmaceuticals International PLC (KNSA). have?

Kiniksa Pharmaceuticals International PLC (KNSA) has 315 emplpoyees as of December 05 2025.

arrow icon

What is Kiniksa Pharmaceuticals International PLC (KNSA) market cap?

Today KNSA has the market capitalization of 3.11B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free